Directory

Harris & Harris Group, Inc., is a publicly traded venture capital firm exclusively focused on investing in companies enabled by nanotechnology and microsystems. With over 30 nanotechnology companies in our portfolio, Harris & Harris Group, Inc., is one of the most active nanotechnology investors in the world. We consider a company to fit our investment thesis if the company employs, intends to employ or enables technology that we consider to be at the microscale, nanoscale or smaller and if the employment of that technology is material to its business plan.

NanoHorizons was founded in 2002 by a team of scientists from The Pennsylvania State University as part of the Centre County Industrial Development Corporation (IDC) incubator program. The company's mission was to develop and commercialize nanomaterial-enabled products based upon an extensive intellectual property portfolio. The early work of the company included the development of high performance flexible electronics, and nanomaterial-based sensors and analytical chemistry devices for drug discovery.

Next generation “High-Quality-Roll2Roll-Beam-Curing-Nanoreplication-Systems”

Nanoptics is an innovative specialist optical technologies equipment and process company, founded in 2008. We developed new technology to bring our partners to the desired capability position - to replicate optical, functional micro and nano structures on Roll2Roll equipment at the ultimate levels of quality and speed.

Nanosys delivers process-ready materials for:

* Electronic device manufacturers seeking LCD displays with better color gamut, efficiency and brightness.
* Lithium ion battery makers aiming to deliver higher battery capacity in consumer electronics.

Optimized for specific properties, Nanosys solutions are tailored to integrate with existing system materials and processes. Backlight display and energy storage manufacturers can deliver superior products using architected materials.

Selecta Biosciences is a clinical-stage biotechnology company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications.

Selecta's proprietary Synthetic Vaccine Particle (SVP™) platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications with the potential for improved efficacy and safety profiles.